[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518461":3},{"organization":4,"outcomesModule":7,"designInfo":39,"detailedDescription":38,"studyPopulation":38,"armGroups":50,"interventions":63,"overallOfficials":71,"centralContacts":75,"locations":82,"responsibleParty":102,"collaborators":38,"id":105,"slug":38,"hasResults":106,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":106,"sex":111,"minAge":112,"maxAge":38,"enrollmentInfo":113,"targetDuration":38,"studyType":116,"phases":117,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":85,"whyStopped":38,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},{"fullName":5,"class":6},"Chulalongkorn University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":38},[9],{"measure":10,"description":11,"timeFrame":12},"MAKE30","The composite outcome of death, new dialysis, and sustained loss of kidney function (which was defined as a 25% or greater decline in eGFR from baseline) assess at 30 days following randomization","30 days",[14,17,19,21,23,26,29,32,34,36],{"measure":15,"description":15,"timeFrame":16},"In-hospital mortality rate","During admission",{"measure":18,"description":18,"timeFrame":12},"30-days mortality rate",{"measure":20,"description":20,"timeFrame":12},"Initiation of Renal Replacement therapy",{"measure":22,"description":22,"timeFrame":12},"Sustained loss of kidney function defined as a 25% or greater decline in eGFR at 30 days following randomisation compared to baseline eGFR",{"measure":24,"description":25,"timeFrame":12},"Recurrent heart failure","Recurrent heart failure required hospital administration",{"measure":27,"description":28,"timeFrame":12},"Vasoactive drug","Vasoactive drug use",{"measure":30,"description":31,"timeFrame":12},"Mechanical ventilation","Mechanical ventilation use",{"measure":33,"description":33,"timeFrame":12},"Ventricular tachycardia or ventricular fibrillation",{"measure":35,"description":35,"timeFrame":12},"Resuscitation following a cardiac arrest",{"measure":37,"description":37,"timeFrame":12},"Reduction of prespecified renal biomarkers",null,{"allocation":40,"interventionModel":41,"interventionModelDescription":38,"primaryPurpose":42,"observationalModel":38,"timePerspective":38,"maskingInfo":43},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":44,"maskingDescription":38,"whoMasked":45},"QUADRUPLE",[46,47,48,49],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[51,57],{"label":52,"type":53,"description":54,"interventionNames":55},"Empagliflozin","EXPERIMENTAL","Empagliflozin 10 mg po OD",[56],"Drug: Empagliflozin 10 MG",{"label":58,"type":59,"description":60,"interventionNames":61},"Placebo","PLACEBO_COMPARATOR","Matching placebo",[62],"Drug: Placebo",[64,68],{"type":65,"name":66,"description":66,"armGroupLabels":67,"otherNames":38},"DRUG","Empagliflozin 10 MG",[52],{"type":65,"name":58,"description":69,"armGroupLabels":70,"otherNames":38},"Matching placebo containing Lactose content (0.26 gram)",[58],[72],{"name":73,"affiliation":5,"role":74},"Nattachai Srisawat","PRINCIPAL_INVESTIGATOR",[76],{"name":77,"role":78,"phone":79,"phoneExt":80,"email":81},"Sasipha Tachaboon","CONTACT","6622564000","73305","sasipha.t@chulahospital.org",[83],{"facility":84,"status":85,"city":86,"state":87,"zip":88,"country":89,"countryCode":90,"cosmosGeoPoint":91,"geoPoint":96,"contacts":97},"Faculty of Medicine, Chulalongkorn University","RECRUITING","Bangkok","Pathumwan","10330","Thailand","TH",{"type":92,"coordinates":93},"Point",[94,95],100.50144,13.75398,{"lat":95,"lon":94},[98],{"name":99,"role":78,"phone":79,"phoneExt":100,"email":101},"Tanat Lertussavavivat","73303","lert.tanat@gmail.com",{"type":74,"investigatorFullName":103,"investigatorTitle":104,"investigatorAffiliation":5,"oldNameTitle":38,"oldOrganization":38},"Nattachai Srisawat ,M.D.","Professor","100518461",false,"NCT06030843","The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1","TREAT-CRS","Inclusion criteria\n\n* Age 18 years or more\n* Hospitalized for the primary diagnosis of acute denovo or decompensated chronic heart regardless of ejection fraction\n* AKI KDIGO any stage or urine NGAL ≥ 150 ng\u002FmL\n* Must be able to be enrolled into the trial ≤ 12 hours of diagnosis of AKI or elevated urine NGAL\n\nExclusion criteria\n\n* Denied to participate in the study\n* Cardiogenic shock or unstable hemodynamic (systolic blood pressure of at least 100 mmHg or required inotropic support within last 24 hours)\n* Cardiac mechanical support (i.e. extracorporeal membrane oxygenation and intra-aortic balloon pump)\n* Acute coronary syndrome\n* Diagnosed with cause of AKI other than cardiorenal syndrome (eg. sepsis, nephrotoxic, dehydration)\n* Anuria or requiring dialysis or expected to required dialysis within 24 hr\n* Baseline eGFR ≤ 20 ml\u002Fmin\u002F1.73m2 with or without dialysis initiated\n* Heart or kidney transplanted\n* Previously received any SGLT2i in the last 3 months before admission\n* Allergic to any SGLT2i\n* Type 1 diabetes mellitus\n* History of ketoacidosis, including diabetic ketoacidosis\n* Pregnancy\n* Comorbid conditions with an expected survival of less than 1 months such as end-stage liver or heart disease, or uncurable malignancy","ALL","18 Years",{"count":114,"type":115},200,"ESTIMATED","INTERVENTIONAL",[118,119],"PHASE2","PHASE3","Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.",[122],"Empagliflozin in Cardiorenal Syndrome Type 1",[52,124,125,126,127],"SGLT2i","Cardiorenal syndrome","ADHF","AKI","2026-06-15",{"date":130,"type":131},"2026-06-16","ACTUAL",{"date":133,"type":131},"2025-03-01",{"date":135,"type":115},"2026-12-31",{"name":5,"class":6},1]